Azra AI vs RhythmX AI (2026)
Both read what is already in the record to make sure someone acts on it, and they enter at different points. Azra reads pathology and radiology reports the moment they arrive and converts findings into assigned work, so a new cancer diagnosis becomes a navigator's task rather than a document nobody opened, and it consumes live interface feeds directly. RhythmX unites data across sources into a precision care platform aimed at primary care physicians, working the panel rather than a service line. For a cancer program losing patients between diagnosis and navigation, Azra is pointed at exactly that. For an organization whose gaps are spread across primary care, RhythmX reaches earlier. Azra publishes almost nothing on privacy or security while consuming live clinical feeds, which is the diligence to do before the integration, not after.
- It reads pathology and radiology reports as they land and turns findings into assigned work, so a newly diagnosed patient becomes someone's responsibility rather than a line in a report.
- It consumes live interface feeds directly rather than querying the record after the fact.
- For a cancer service line, the failure it addresses is patients falling through the gap between diagnosis and navigation, which is a documented and expensive problem.
- It unites data across sources into a precision care platform aimed at the primary care physician rather than at a service line.
- Primary care is where most missed follow up originates, so acting there reaches patients before a specialist is involved at all.
- The breadth suits an organization trying to lift care gaps across a panel rather than to route one disease pathway.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Azra AI and RhythmX AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Azra AI | RhythmX AI |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | 2022 | 2023 |
| Headquarters | Nashville, Tennessee, United States | Palo Alto, CA, US |
| Website | azra-ai.com | rhythmx.ai |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Azra AI
-
Acquisition / corporate
Azra AI completed its acquisition of Blackford Analysis, whose platform offers more than 130 imaging AI applications from over 45 partner vendors.
Source -
EHR / interoperability
Azra AI has integrated its care orchestration platform with Blackford's portfolio of over 130 medical imaging AI applications.
Source -
EHR / interoperability
Azra AI has partnered with RevealDx to integrate the mSI score for characterizing suspicious cancerous lung lesions into its oncology platform.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Azra AI reads pathology and radiology reports as they land in the record and turns what it finds into work someone is accountable for. Founded in 2022 in Tennessee by Chris Cashwell, formerly named Invenero Holdings, the company describes clinically trained natural language models that identify newly diagnosed cancers and suspicious incidental findings, and publishes a headline precision figure of 99 percent.
Source: AI Health Index, August 2026
RhythmX AI sells a precision care platform for primary care. It reads a patient's record, the visit and data from more than ten sources, including guidelines, payer and formulary rules, and social and lifestyle factors, and returns patient-specific recommendations: labs, imaging, medications, follow-ups, care gaps, coding and documentation opportunities, and routing to the right clinician.
Source: AI Health Index, August 2026
Questions buyers ask
How do Azra AI and RhythmX AI work with the EHR?
For Azra AI, the incidental findings page says radiology reports stream in over HL7 and FHIR from Cerner, Epic or any source system, are processed in real time and routed into care pathways, and that every action is written back so clinicians do not document twice. The oncology product surfaces patients from the record at diagnosis and sends documentation back into it.
Presbyterian's clinicians use the platform in a consolidated workflow inside Epic, and RhythmX Pulse consumes the encounter captured by Dragon Copilot; the privacy policy says the AI reads structured and unstructured record data through standard interfaces. The company calls the platform EHR agnostic without naming another EHR, and nothing says whether accepted recommendations are written back to the chart. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Azra AI and RhythmX AI priced and sold?
In Azra AI's case, a separate services menu sells people as well as software: strategic execution, clinical and non clinical navigation, tumor board support and cancer registry case finding. The route in is an enterprise review, so this is sold as a platform plus managed services to health systems.
The platform is sold to health systems, and since July 2026 RhythmX Pulse can be added through Microsoft Marketplace by health systems already using Dragon Copilot, with no separate implementation. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Azra AI and RhythmX AI handle patient data?
With Azra AI, the privacy policy, last updated March 2026, is a short notice about contact information collected from website visitors and prospective customers, with a generic data security paragraph; it does not address pathology reports, radiology reports or patient data at all.
In RhythmX AI's case, retention periods themselves are left to each agreement. The company also markets access to its group's longitudinal data on 300 million patients and 4.4 billion annual claims without saying where it came from. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Azra AI and RhythmX AI cover?
For Azra AI, the core is the service line from the report that carries a new cancer diagnosis through navigation, tumor boards, follow up and registry reporting.
With RhythmX AI, the platform targets primary care physicians, advanced practice providers and care teams managing chronic conditions, and routes to specialists; Presbyterian's 200 primary care clinicians are the named deployment and Sentara Health selected it for a primary care pilot in September 2026. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Azra publishes no health privacy statement, business associate terms, security attestation, retention position or secondary use policy across repeated searches, which is a wide gap for a platform consuming live pathology and radiology feeds across a health system.
Neither vendor publishes a subgroup performance analysis, and for models reading free text reports the predictable failure is systematic: reports written in unusual formats or by particular services are read less reliably, and the patients behind those reports are missed without any signal. Neither publishes pricing. Ask both what proportion of surfaced cases turn out to be actionable.